Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 891-898

  Witte, David G ^a   Brune, Michael E ^a   Katwala, Sweta P ^a   Milicic, Ivan ^a   Kerwin Jr , James F ^a   Hancock, Arthur A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLEPHRINE; TERAZOSIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTERY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URETHRA; URETHRA PRESSURE;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DOGS; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; URETHRA;

EID: 0030754099     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. AKAIKE, A.: Posterior probabilities for choosing a regression model. Ann. Inst. Math. Stat. 30: A9-14, 1978.
2. BRUNE, M. E., KATWALA, S. P., MILICIC, I., BUCKNER, S. A., IRELAND, L. M., J. F. KERWIN, JR. AND HANCOCK, A. A.: Simultaneous evaluation of the effects of alpha1-adrenergic antagonists on vascular and prostatic smooth muscle in intact conscious dogs. Pharmacology 53: 356-368, 1996.
3. DUZENDORFER, U.: Effects of terazosin in the treatment of benign prostatic hyperplasia: A pilot study. Arzneimittel-Forsch. 39: 1289-1291, 1989.
4. FABRICIUS, P. G., WEIZERT, P., DUZENDORFER, U., MACHANNAFORD, J. M. AND MAURATH, C.: Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomised, double-blind placebo-controlled clinical trial. Prostate 3 (Suppl.): 85-93, 1990.
5. HANCOCK, A. A., BUCKNER, S. A., IRELAND, L. M., KNEPPER, S. M. AND J. F. KERWIN, JR.: Actions of terazosin and its enantiomers at subtypes of α1-and α2-adrenoceptors in vitro. J. Recept. Signal Transd. Res. 15: 863-885, 1995.
6. HOLFORD, N. H. AND SHEINER, L. B.: Understanding the dose-effect relationship. Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6: 429-453, 1981.
7. JUNGERS, P., GANEVAL, D., PERTUISET, N. AND CHAUVEAU, P.: Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. Am. J. Med. 80: 94-99, 1986.
8. KAPLAN, S. A., SOLDO, K. A. AND OLSSON, C. A.: Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety. Eur. Urol. 28: 223-228, 1995.
9. KENNY, B. A., NAYLOR, A. M., CARTER, A. J., READ, A. M., GREENGRASS, P. M. AND WYLLIE, M. G.: Effect of alpha1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 44: 52-57, 1994.
10. KYNCL, J. J., SONDERS, R. C., SPERZEL, D. W., WINN, M. AND SEELY, J, H.: Terazosin. In New Cardiovascular Drugs, ed. by Alexander Scriabine, pp. 1-18, Raven Press, New York, 1986.
11. LEFEVRE-BORG, F., LECHAIRE, J. AND O'CONNOR, S.: In vivo uroselectiviy of alfuzosin compared to prazosin and terazosin. Br. J. Pharmacol. 106s: 84P, 1992.
12. LEPOR, H., AUERBACH, S., PURAS-BAEZ, A., NARAYAN, P., SOLOWAY, M., Lows, F., MOON, T., LEIFER, G. AND MADSEN, P.: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 148: 1467-1474, 1992.
13. PATTERSON, S. E.: Rapid and sensitive analysis of terazosin in plasma, peritoneal dialysis solution, and urine using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 311: 206-212, 1984.
14. PATTERSON, S. E.: Terazosin kinetics after oral and intravenous doses. Clin. Pharmacol. Ther. 38: 423-427, 1985.
15. ROWLAND, M. AND TOZER, T. N.: Clinical Pharmacokinetics: Concepts and Applications, 3rd ed., pp. 84-91, Lea & Febiger, Philadelphia, 1995.
16. SHIBASAKI, M., SUDOH, K., INAGAKI, O., UCHIDA, W. AND HONDA, K.: Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs. J. Auton. Pharmacol. 12: 263-268, 1992.
17. SONDERS, R. C.: Pharmacokinetics of terazosin. Am. J. Med. 80: 20-24, 1986.
18. TAKENAKA, T., FUJIKURA, T., HONDA, K, ASANO, M. AND NIIGATA, K.: Discovery and development of tamsulosin hydrochloride, a new α1-adrenoceptor antagonist. Yakugaku Zasshi 115: 773-789, 1995.
19. TESTA, R., SIRONI, G., COLOMBO, D., GRETO, L. AND LEONARDI, A.: REC 15/273, a new α1-antagonist selective for the lower urinary tract: In vivo studies. Neurourol. Urodynam. 13: 471-473, 1994.
20. TITMARSH, S. AND MONK, J. P.: Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 33: 461-477, 1987.
21. VARGAS, H. M. AND GORMAN, A. J.: Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci. 57: 2291-2308, 1991.
22. WELLING, P. G.: Pharmacokinetics: Processes and Mathematics, 1st ed., p. 146, American Chemical Society, Washington, DC, 1986.
23. WILDE, M. I., FITTON, A. AND SORKIN, E. M.: Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drug Aging 3: 258-277, 1993.